The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Have type 2 diabetes
Have an HbA1c ≥7.5% to ≤10.5% at screening
Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
Diet and exercise
Have any form of diabetes other than type 2 diabetes
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
acute myocardial infarction
cerebrovascular accident (stroke)